Bioequivalence Study of Paracetamol Orodispersible Tablets 500 mg Versus Apiretal 100 mg/mL Oral Solution in Fasting Healthy Volunteers

The primary objective of this study is to assess the **bioequivalence** of paracetamol orodispersible tablets 500 mg compared to Apiretal® 100 mg/ml oral solution in healthy volunteers under fasting conditions. Bioequivalence studies are clinically relevant as they ensure that different formulations of a drug release the active ingredient into the bloodstream at the same rate and extent, which is crucial for maintaining therapeutic efficacy and safety. No secondary objectives are provided for this study.

The clinical trial involves **healthy volunteers** under fasting conditions, with both male and female participants included. The study population falls within the age range category of 18 to 65 years. The trial does not focus on a vulnerable population, and the selection process for participants has not been detailed by the sponsor. The total number of participants has not been provided. Participants are expected to maintain a fasting state, which is a relevant lifestyle consideration for this study. The sponsor has not disclosed specific inclusion or exclusion criteria for this trial.

The clinical trial is designed as a **randomized**, open-label, three-way crossover study to evaluate the **bioequivalence** of paracetamol orodispersible tablets 500 mg compared to Apiretal® 100 mg/ml oral solution in **healthy volunteers** under fasting conditions. The trial is categorized as a Phase 2 study and is expected to commence recruitment on September 30, 2023, with an estimated completion date of December 31, 2023. The study involves a sequence of visits, beginning with an inclusion visit where participants are screened for eligibility based on predefined criteria. This is followed by the administration of the investigational products in a randomized order, with each participant receiving all formulations in different periods, separated by appropriate washout intervals to prevent carryover effects.

Participants will attend multiple study visits, including follow-up visits after each dosing period to monitor safety and collect pharmacokinetic data. The end-of-study visit will conclude the trial, where final assessments are conducted to ensure participant safety and gather any remaining data. The expected duration of participant involvement is contingent upon the completion of all dosing periods and follow-up assessments, typically spanning several weeks. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure the collection of robust data while maintaining participant safety and adherence to ethical standards.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on September 30, 2023, with an estimated completion date of December 31, 2023. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact over the course of the study, adhering to the protocols typical of a Phase 2 trial. The trial's design will ensure that efficacy is measured in a scientifically rigorous manner, consistent with clinical research standards.